AU2003236646B2 - Recombinant poxvirus expressing homologous genes inserted into the poxviral genome - Google Patents

Recombinant poxvirus expressing homologous genes inserted into the poxviral genome Download PDF

Info

Publication number
AU2003236646B2
AU2003236646B2 AU2003236646A AU2003236646A AU2003236646B2 AU 2003236646 B2 AU2003236646 B2 AU 2003236646B2 AU 2003236646 A AU2003236646 A AU 2003236646A AU 2003236646 A AU2003236646 A AU 2003236646A AU 2003236646 B2 AU2003236646 B2 AU 2003236646B2
Authority
AU
Australia
Prior art keywords
recombinant poxvirus
genes
recombinant
virus
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003236646A
Other languages
English (en)
Other versions
AU2003236646A1 (en
Inventor
Paul Howley
Sonja Leyrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of AU2003236646A1 publication Critical patent/AU2003236646A1/en
Priority to AU2008255213A priority Critical patent/AU2008255213B2/en
Application granted granted Critical
Publication of AU2003236646B2 publication Critical patent/AU2003236646B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003236646A 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome Expired AU2003236646B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008255213A AU2008255213B2 (en) 2002-05-16 2008-12-09 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200200753 2002-05-16
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16
DKPA200200752 2002-05-16
PCT/EP2003/005047 WO2003097846A1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008255213A Division AU2008255213B2 (en) 2002-05-16 2008-12-09 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Publications (2)

Publication Number Publication Date
AU2003236646A1 AU2003236646A1 (en) 2003-12-02
AU2003236646B2 true AU2003236646B2 (en) 2009-01-15

Family

ID=29551228

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2003236646A Expired AU2003236646B2 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
AU2003242540A Abandoned AU2003242540A1 (en) 2002-05-16 2003-05-14 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
AU2008255213A Expired AU2008255213B2 (en) 2002-05-16 2008-12-09 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
AU2009200380A Expired AU2009200380C1 (en) 2002-05-16 2009-02-03 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2003242540A Abandoned AU2003242540A1 (en) 2002-05-16 2003-05-14 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
AU2008255213A Expired AU2008255213B2 (en) 2002-05-16 2008-12-09 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
AU2009200380A Expired AU2009200380C1 (en) 2002-05-16 2009-02-03 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)

Country Status (22)

Country Link
US (14) US7550147B2 (enExample)
EP (3) EP1506301B1 (enExample)
JP (4) JP4693092B2 (enExample)
KR (4) KR101005630B1 (enExample)
CN (6) CN101831411A (enExample)
AT (1) ATE315660T1 (enExample)
AU (4) AU2003236646B2 (enExample)
BR (2) BR0310051A (enExample)
CA (3) CA2812019A1 (enExample)
DE (1) DE60303218T2 (enExample)
DK (2) DK1506301T3 (enExample)
EA (3) EA020230B1 (enExample)
ES (1) ES2256776T3 (enExample)
IL (4) IL164177A0 (enExample)
MX (2) MXPA04011194A (enExample)
NO (3) NO334273B1 (enExample)
NZ (2) NZ536501A (enExample)
PL (2) PL218318B1 (enExample)
PT (1) PT1407033E (enExample)
SI (1) SI1407033T1 (enExample)
UA (1) UA82479C2 (enExample)
WO (2) WO2003097845A1 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (enExample) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
CN101676389A (zh) * 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
DK1420822T4 (en) * 2002-04-19 2017-10-09 Bavarian Nordic As Modified vaccinia virus Ankara for vaccination of newborns
PL218318B1 (pl) * 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003264144C1 (en) * 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
EP1601333B1 (en) * 2003-02-20 2013-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
EP1807508A4 (en) * 2004-11-05 2008-03-12 Us Gov Health & Human Serv METHODS FOR PREPARING CELLS AND VIRUSES
UA100836C2 (ru) * 2005-02-23 2013-02-11 Бавариан Нордик А/С Применение модифицированного вируса осповакцины анкара (mva) для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
BRPI0711898A2 (pt) * 2006-05-19 2011-12-27 Glycofi Inc composiÇço de proteÍna da eritropoietina substancialmente homogÊnea, composiÇço farmacÊutica, e, mÉtodos de aumentar hematàcrito em um mamÍfero, e de produzir uma composiÇço de eritropoietina
WO2008142479A2 (en) 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
ES2517615T3 (es) * 2006-11-09 2014-11-03 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
PE20081723A1 (es) * 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
BRPI0810305A2 (pt) * 2007-05-15 2018-07-10 Transgene Sa "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
KR20100038323A (ko) * 2007-05-30 2010-04-14 와이어쓰 엘엘씨 고양이 항원의 유전자를 발현하는 라쿤 폭스바이러스
US7867483B2 (en) 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
WO2010057650A1 (en) * 2008-11-21 2010-05-27 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
US20110159031A1 (en) * 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
AU2011305348A1 (en) * 2010-09-23 2013-04-18 Baxter Healthcare Sa Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US20150150963A1 (en) 2012-06-05 2015-06-04 The Australian National University Vaccination with interleukin-4 antagonists
EA201891945A3 (ru) 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2014138824A1 (en) * 2013-03-15 2014-09-18 Sementis Limited Immune modulation
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
CA3011014A1 (en) 2016-01-08 2017-07-13 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
WO2017129765A1 (en) * 2016-01-29 2017-08-03 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
MX2018013340A (es) 2016-05-02 2019-08-21 Janssen Vaccines & Prevention Bv Combinaciones de vacunas terapeuticas para el vph.
NZ750578A (en) * 2016-08-19 2023-05-26 Sementis Ltd Viral vaccines
US20200024610A1 (en) * 2016-09-30 2020-01-23 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
BR112019026126A2 (pt) * 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
WO2019217922A1 (en) 2018-05-11 2019-11-14 City Of Hope Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof
MX2021003013A (es) 2018-09-15 2021-08-11 Memorial Sloan Kettering Cancer Center Poxvirus recombinantes para inmunoterapia contra cáncer.
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
EP3842065A1 (en) * 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
IL295482A (en) 2020-02-14 2022-10-01 Geovax Inc Vaccines and their uses to induce an immune response to sars-cov2
TW202203966A (zh) * 2020-03-31 2022-02-01 澳大利亞商賽門蒂斯公司 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
CA3206004A1 (en) 2021-02-02 2022-08-11 Mary Jo Hauser Viral constructs for use in enhancing t-cell priming during vaccination
CN120676952A (zh) 2022-07-08 2025-09-19 维罗米梭公司 溶瘤痘苗病毒及其重组病毒和使用方法
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5494807A (en) * 1991-03-07 1996-02-27 Virogenetics Corporation NYVAC vaccinia virus recombinants comprising heterologous inserts
WO1998013500A2 (en) * 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US5744141A (en) * 1990-08-15 1998-04-28 Virogenetics Corporation Flavivirus recombinant poxvirus immunological composition
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
EP0597016A4 (en) 1991-07-26 1996-04-24 Virogenetics Corp Infectious bursal disease virus recombinant poxvirus vaccine.
EP1380651A2 (en) * 1991-08-26 2004-01-14 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
DE60040662D1 (de) * 1999-05-28 2008-12-11 Helmholtz Zentrum Muenchen Vektor zur integration von heterologen sequenzen in poxvirusgenomen
RU2280075C2 (ru) * 2000-03-14 2006-07-20 Бавариан Нордик А/С Измененный штамм модифицированного вируса коровьей оспы ankara (mva)
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
PL218318B1 (pl) * 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
AU2003293675B2 (en) * 2002-11-25 2009-04-23 Bavarian Nordic A/S Recombinant poxvirus comprising at least two cowpox ATI promoters

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5744141A (en) * 1990-08-15 1998-04-28 Virogenetics Corporation Flavivirus recombinant poxvirus immunological composition
US5494807A (en) * 1991-03-07 1996-02-27 Virogenetics Corporation NYVAC vaccinia virus recombinants comprising heterologous inserts
WO1998013500A2 (en) * 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
WO2002018585A2 (en) * 2000-08-29 2002-03-07 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Howely et al, J of Virology Methods (1999), 79: 65-74 *

Also Published As

Publication number Publication date
PL216760B1 (pl) 2014-05-30
KR20040108809A (ko) 2004-12-24
US8309326B2 (en) 2012-11-13
JP4693092B2 (ja) 2011-06-01
US20120135501A1 (en) 2012-05-31
SI1407033T1 (sl) 2006-06-30
IL193087A0 (en) 2009-02-11
EP2253709A1 (en) 2010-11-24
PL218318B1 (pl) 2014-11-28
HK1076836A1 (zh) 2006-01-27
WO2003097846A1 (en) 2003-11-27
BRPI0311178B1 (pt) 2020-11-17
IL193087A (en) 2012-10-31
US7964374B2 (en) 2011-06-21
ATE315660T1 (de) 2006-02-15
UA82479C2 (uk) 2008-04-25
DK1407033T3 (da) 2006-05-22
AU2009200380B2 (en) 2009-10-01
US8435543B2 (en) 2013-05-07
EP1506301B1 (en) 2014-04-30
US20120082696A1 (en) 2012-04-05
JP2005525823A (ja) 2005-09-02
IL164177A0 (en) 2005-12-18
US20120039936A1 (en) 2012-02-16
NO20044940L (no) 2004-11-12
US20060165727A1 (en) 2006-07-27
EP2253709B1 (en) 2018-04-11
CA2812019A1 (en) 2003-11-27
US20090311746A1 (en) 2009-12-17
JP2005525822A (ja) 2005-09-02
US20050244428A1 (en) 2005-11-03
AU2009200380C1 (en) 2010-03-11
US9109233B2 (en) 2015-08-18
US8034354B2 (en) 2011-10-11
CN102703393A (zh) 2012-10-03
CA2481799C (en) 2014-01-28
EA200401506A1 (ru) 2005-04-28
US20100173388A1 (en) 2010-07-08
CA2481521C (en) 2012-04-17
US20110053260A1 (en) 2011-03-03
CN101831411A (zh) 2010-09-15
EP1407033B1 (en) 2006-01-11
BR0310051A (pt) 2005-02-15
DE60303218T2 (de) 2006-09-14
CN1653183B (zh) 2012-07-25
ES2256776T3 (es) 2006-07-16
IL193088A (en) 2015-02-26
US20120178157A1 (en) 2012-07-12
US7550147B2 (en) 2009-06-23
KR20120002627A (ko) 2012-01-06
BRPI0311178B8 (pt) 2021-05-25
US20100303856A1 (en) 2010-12-02
NZ536501A (en) 2006-08-31
US20110244574A1 (en) 2011-10-06
KR101041691B1 (ko) 2011-06-14
KR101005630B1 (ko) 2011-01-05
CN102199628A (zh) 2011-09-28
AU2008255213A1 (en) 2009-01-08
NO20111324A1 (no) 2011-09-29
KR101138067B1 (ko) 2012-04-24
DE60303218D1 (de) 2006-04-06
IL193088A0 (en) 2009-02-11
US8741308B2 (en) 2014-06-03
US7338662B2 (en) 2008-03-04
NO336489B1 (no) 2015-09-07
KR20100110901A (ko) 2010-10-13
JP4895505B2 (ja) 2012-03-14
AU2009200380A1 (en) 2009-02-19
NO334273B1 (no) 2014-01-27
CN102719408A (zh) 2012-10-10
CN100494388C (zh) 2009-06-03
EP1407033A1 (en) 2004-04-14
CA2481799A1 (en) 2003-11-27
NO20045480L (no) 2004-12-16
CA2481521A1 (en) 2003-11-27
JP2011004755A (ja) 2011-01-13
PL372093A1 (en) 2005-07-11
AU2003236646A1 (en) 2003-12-02
EA200900180A1 (ru) 2009-08-28
JP5777199B2 (ja) 2015-09-09
EA012160B1 (ru) 2009-08-28
EA007811B1 (ru) 2007-02-27
AU2003242540A1 (en) 2003-12-02
CN1653183A (zh) 2005-08-10
US20110250693A1 (en) 2011-10-13
DK1506301T3 (da) 2014-07-21
AU2008255213B2 (en) 2011-10-06
MXPA04010713A (es) 2005-03-07
EP1506301A1 (en) 2005-02-16
MXPA04011194A (es) 2005-02-14
NZ536502A (en) 2005-10-28
US8288125B2 (en) 2012-10-16
HK1076642A1 (en) 2006-01-20
PT1407033E (pt) 2006-05-31
KR20040108798A (ko) 2004-12-24
US8414900B2 (en) 2013-04-09
IL164172A0 (en) 2005-12-18
BR0311178A (pt) 2005-03-29
US20110053259A1 (en) 2011-03-03
WO2003097845A1 (en) 2003-11-27
EA200401507A1 (ru) 2005-06-30
EA020230B1 (ru) 2014-09-30
CN1653184A (zh) 2005-08-10
US20130243813A1 (en) 2013-09-19
PL372088A1 (en) 2005-07-11
JP2010259446A (ja) 2010-11-18

Similar Documents

Publication Publication Date Title
CA2481799C (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
HK1076642B (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
HK1144700A (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
HK1156979A (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
HK1171249A (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
HK1170772A (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired